Podcasts about Roeland

Er staat weer een nieuw Top 40 Weekoverzicht voor je klaar! Qmusic-dj Stephan Bouwman praat je bij over een nieuwe Top 40 en alle hoogtepunten van deze week. Met deze week: een online relletje rondom de nieuwe track van Calvin Harris, een interview met Jopke en Roeland over hun carrière na Lotje, en een nieuwe nummer #1! Je hoort het allemaal, in dit nieuwe Top 40 Weekoverzicht! En de volledige Nederlandse Top 40? Die hoor je iedere vrijdagmiddag tussen 14:00 uur en 18:00 uur op Qmusic.See omnystudio.com/listener for privacy information.

Whatsapp Bandits!! Onze nieuwe remix van Lotje is nu te beluisteren en de downloaden via SoundCloud, maar let op! Het is slechts via SoundCloud beschikbaar tot Maandagochtend 00:00. Daarna verdwijnt de link naar Hypeddit. Check onze tech house remix van Lotje nu hier! Have fun!

Roeland Van Wijk, PhD, is a world leader in the field of biophotons. He has a background in biology and is specialised in physical science (biophysical chemistry). He was affiliated as Associate Professor in Molecular Cell Biology at the Utrecht University until his retirement. Roeland worked closely with many pioneers including Fritz Popp and Mae-Wan Ho as they uncovered unsurpassed insights into the nature of the coherent energy fields associated with biological systems; particularly photonic fields. His background and experience is extremely broad, with a deep understanding of biological water, the extracellular matrix and quantum biology. His seminal work, “Light in Shaping Life: Biophotons in Biology & Medicine (2014)” remains the most comprehensive historical introduction in biophoton research.Biophotons are spontaneous emissions of light that originate from reactive oxygen species, particularly in the mitochondria. These emissions are a substrate for cellular and subcellular communication as well as vital energetic inputs within the body, serving to imbue surrounding molecules with quantised energy.Please consider subscribing to my Substack where I share my detailed thoughts and insights on my podcast topics and beyond. This is the best way to support me and the podcast. https://ricciflow.substack.com/Roeland's WorkBooksPublicationsFollow MeWebsiteSubstackConsultationInstagramYoutubeTwitter/XSpotifyAppleLinktree

Als voormalig Country Manager van Amazon Nederland en met een achtergrond als advocaat bij Allen & Overy, weet Roeland als geen ander hoe strategie, juridische kennis en ondernemerschap samenkomen in de boardroom én op de veilingvloer. Met merken als Troostwijk Veilingen, Vavato en British Medical Auctions onder zijn hoede, stuurt Roeland een team van ruim 350 collega's aan, verspreid over Nederland, België en het Verenigd Koninkrijk. Hij staat aan het roer van een snelgroeiende organisatie waar technologie, data en slimme verkoopkansen samenkomen. Hoe blijf je als platform toekomstbestendig in een snel digitaliserende markt? Wat zijn de grootste uitdagingen én kansen bij het combineren van data-gedreven besluitvorming met menselijke expertise en hoe zorgt TBAuctions ervoor dat het zijn leidende positie in Europa niet alleen behoudt, maar ook verder uitbouwt? Van A tot Z Succesvol inspireert leiders om nog beter te worden in het managen of coachen van zichzelf en hun team. Met inspirerende studiogasten, eyeopeners en veel voorbeelden en ervaringen uit de praktijk. Er wordt ingegaan op wat succes nu eigenlijk is, wat betekent het voor je en hoe ga je er mee om?  Het programma is elke tweede donderdag van de maand tussen 11:00 en 12:00 uur te beluisteren op New Business Radio en wordt naderhand ook als podcast beschikbaar gesteld.

Beste LuisteraarZZ,Welkom bij seizoen 2 aflevering 14 van de Zorg en Zekerheid Leiden basketbal podcast! In deze aflevering zal ik samen met Arie in t Veld en onZZe captain Roeland schaftenaar het volgende behandelen; we bespreken de afgelopen wedstrijden tegen Leuven, Bal Weert, QSTA united en blikken vooruit op de wedstrijd van as zaterdag tegen Union Mons-Hainaut en wat er verder nog op tafel komt. Blijf op de hoogte, blijf betrokken en laten we samen genieten van al het mooie wat ZZ Leiden met zich mee brengt. Kaarten bestel je via: ZZ Leiden | BestelformulierVrijwilliger worden: ZZ Leiden | VrijwilligersSupportersvereniging de Blauwe Brigade: https://www.deblauwebrigade.nl/De FanZZshop: https://www.shirtprintservice.nl/zzleiden-shopKom jij de dames van ZZ Leiden basketbal de eerst volgende thuiswedstrijd ook aanmoedigen? info: https://leidenbasketballdames.nl/ Heb je vragen, opmerkingen, suggesties of zelfs discussiepunten? Mail dan naar: zzleidenpodcast@hotmail.com Deze podcast wordt mede mogelijk gemaakt door:Leidse Letselschade advocaten: https://leiden-letselschadeadvocaten.nl/Van dorp kentekenplaten: https://www.vandorp.nl/Createx: http://www.createx4food.com/Lewo bouwbedrijf: Lewo (lewobv.nl)Versteegenautos: https://www.versteegenautos.nl

Vandaag kruipen we backstage. Onze gast tourde jarenlang met grote artiesten. Stond aan de wieg van Het Depot in Leuven en ontwikkelde daarna een SaaS platform voor tourende bands. Van tourmanager tot tech ondernemer, welkom in het verhaal van Roeland Veugelen. Timestamps:0:00 – Introductie en welkom1:52 – Wie is Roeland Veugelen?3:15 – Hoe hij tourmanager werd voor Mylo6:40 – Wat doet een tourmanager eigenlijk allemaal?10:05 – De dynamiek achter de schermen van een internationale tour14:30 – Hoe ziet een typische dag eruit on the road?17:45 – Over nachtbussen, jetlags en onderweg zijn met een crew22:10 – De mooiste (en minst glamoureuze) momenten uit het tourleven26:35 – Wat Roeland leerde van touren op hoog niveau30:05 – De overstap naar Het Depot en het verschil met het leven on the road33:10 – Wat maakt een concertzaal als Het Depot uniek volgens Roeland37:25 – Over samenwerken met artiesten en verwachtingen managen41:50 – Wat het werk achter de schermen zo boeiend maakt45:40 – Waarom de juiste attitude belangrijker is dan ervaring49:30 – Roeland over loslaten, stress en leren relativeren53:20 – Advies voor wie wil starten in de live sector56:10 – Waar je Roeland kan volgen en outroDeze podcast is een initiatief van Webhero, de digitale held van zelfstandigen en KMO's. Wij bouwen websites en webshops en zorgen ervoor dat deze hoog scoren in Google. Weekly Webhero is een podcast voor ondernemers die meer willen leren over marketing en sales.Website: www.webhero.beDeze podcast is te beluisteren op Spotify en Apple podcasts.Roeland Veugelen - Tourmanagementwww.tourmanagement.com

We spreken over zijn musicaldebuut in '40-45', zijn liefde voor kunst en kunstmatigheid, zijn afkeer van gedoe, en hoe hij naarmate hij ouder wordt, steeds beter is geworden in plezier hebben. 'Als ik zo doorga, sterf ik als een blij ei.'

Sign up for SafetyWing here:  https://safetywing.com/?referenceID=26217098&utm_source=26217098&utm_medium=Ambassador   Sign up Traveling Mailbox: https://travelingmailbox.com/?ref=3419   ================================= How to work with me: =================================

Hey, it's Dr. Aumatma, host of Egg Meets Sperm, the podcast where we provide holistic fertility advice for you and your partner—because fertility takes two! In today's episode, I'm thrilled to welcome Dr. Roeland to discuss one of the leading causes of infertility: PCOS (Polycystic Ovary Syndrome). If you've been diagnosed or suspect you have PCOS, this episode is for you! We dive deep into how PCOS affects ovulation, hormones, and fertility, and discuss practical steps you can take to improve your chances of conceiving naturally.We also explore the misunderstood aspects of PCOS, the role of supplements like inositol and NAC, and why you might want to consider continuous glucose monitoring (CGM) to understand your metabolic health. If you're navigating PCOS, this episode is packed with actionable tips to support your journey.Key topics covered:PCOS and its impact on ovulation and fertilityWhy many women with PCOS are undiagnosed and how it affects their fertility journeyThe relationship between insulin resistance and androgen excess in PCOSHow to break the "vicious cycle" of hormonal imbalance in PCOSNatural options for managing PCOS and boosting ovulationThe hidden gift of PCOS: understanding your extra folliclesSupplements for PCOS and fertility: inositol, omega-3s, NAC, vitamin D, and moreUsing continuous glucose monitors (CGMs) to understand your body's needsThe importance of preconception health and lab testing for women with PCOSFollow Dr Jennifer Roelands on: @drjen.mdLet's chat! I want to hear from you! Send me a voice memo with:- what you loved- what you want to see improve- any guests you want me to bring on- AND any questions you want me to cover on the podcast!Did you know you can join my private community to support you in getting Fertile As F***? This is the place for live interactions, support, and learning on the fertility journey.Want more amazing content? Join me on IG.If you found this podcast episode useful, we'd love it if you could take 15 seconds to give us a positive review on whichever platform you're listening to this episode.

Deze keer ben ik in gesprek met Maureen. Wat een bewogen jeugd heeft zij gehad! Ze is op haar vierde uit huis geplaatst en via twee tehuizen bij haar pleegouders terecht gekomen. Ze vertelt hier heel open en eerlijk over. Ze heeft inmiddels zelf een gezin met Roeland, twee dochters van 7 en 9 jaar oud.Haar jongste is hoogbegaafd en van de oudste vermoedt ze het ook. Van wie ontving ze liefde in haar jeugdjaren?Waarom koos ze juist voor een studie pedagogiek? Wat is haar doel met het doen van een opleiding bij RITHA op dit moment? Hoe heeft zij haar hoogbegaafdheid ontdekt? Waarin herkent ze hoogbegaafd zijn?Dit en meer! www.hoogbegaafddegids.nlInstagram @hoogbegaafddegids 

In deze laatste aflevering in de reeks "Lessen van de crises", gaan we langs bij Roeland Voerman van Fred Developers. Hij leidt ons rond in misschien wel het mooiste kantoor van Amsterdam. We hebben het over zijn ondernemersverhalen met zijn bekendste ontwikkeling Nieuw Kijkduin in Den Haag, maar ook over de moeilijkere tijden in het verleden!

Stel, je gaat op je 20e op stage van het Wellantcollege naar Kenia, en ziet wat er daar moet gebeuren om water weer vast te houden en bodems te verbeteren. Dat gebeurt vaker, je schrijft dat verslag en klaar. Maar, Roeland besloot om vanaf dat moment elke cent die hij had te sparen en alles in het werk te stellen om die verandering vervolgens te gaan bewerkstelligen. Niet een paar jaar, maar vanaf 2005 tot nu. Roeland vertelt over zijn zeer bijzondere levenspad of het de gewoonste zaak van de wereld is. Maar dat is het natuurlijk niet. Wie kan ergens halverwege zijn werkzame leven zeggen dat hij de ecologie en welvaart voor de inwoners van 600km2 in Kenia compleet heeft helpen veranderen? En wie zegt dan vervolgens dat hij nu wil gaan werken aan het ontwikkelen van meer regionale economie? Luister naar het bijzondere brein en verhaal van Roeland Lelieveld. Lees alles over Africa Woodgrow op https://foundation.africawoodgrow.org/ Of bekijk de inspirerende filmpjes die in de loop van de jaren zijn gemaakt op https://www.youtube.com/@africawoodgrow

Patrick Malloy, Alicia Eastman, and Chris Jackson speak with Topsoe CEO Roeland Baan about new technologies and new projects, leveraging his expansive background and the assets of an 84 year old science and innovation institution, to tackle climate change. About Roeland Baan: Roeland joined Topsoe as President and CEO in 2020 with a clear focus on establishing the company as a leader in technologies and solutions for the energy transition. He is heading the company's nearly 3,000 employees across a dozen countries to rewrite the future of fuels production.   
Roeland engages in dialogues and forums with other key opinion leaders to identify and deploy solutions that enable the global energy transition. He often shares his perspectives on matters ranging from decarbonization of energy-intensive industries to electrolyzer capacity, new technologies that support carbon emission reductions, and the challenges and regulatory frameworks needed to achieve a fair and inclusive green energy transition.   Roeland has more than 40 years of experience developing businesses, supporting customer relationships, driving growth, building cohesive organizations and amassing deep operational and strategic knowledge across the energy, fuel and steel industries. Prior to joining Topsoe, he was President and CEO of Outokumpu, a producer of stainless steel, and before that CEO of rolled and extruded products at aluminum manufacturer Aleris. Roeland also held leadership positions at Arcelor Mittal, SHV NV and Shell.   He serves as Chairman of SBM Offshore NV and is member of the Syensqo Board of Directors and the Hydrogen Council Board. Roeland earned an M.S. in economics from Vrije Universiteit, Amsterdam.About Topsoe:Topsoe is a leading global provider of technology and solutions for the energy transition. They combat climate change by helping customers and partners achieve their decarbonization and emission reduction goals.Based on decades of scientific research and innovation, they offer world leading solutions for transforming renewable resources into fuels and chemicals for a sustainable world, and for efficient and low-carbon fuel production as well as clean air.Haldor Topsoe founded the company in 1940 and with headquarters in Denmark, Topsoe has nearly 3,000 employees serving customers all around the globe.--Links:Topsoehttps://www.topsoe.com/

Acteur Roeland Fernhout is vanaf deze week op Netflix te zien in een nieuwe reeks van de serie Costa!!. Als twintiger werd hij van de toneelschool geplukt om mee te spelen in de lowbudget-film Zusje, die in 1995 een Gouden Kalf won. Hij bouwde een veelkleurige carrière op; was te zien in klassieke Shakespeare-vertolkingen, maar ook in tv-series als All Stars en De droom van de jeugd. Als tiener zag hij een stuk van De Appel, ervoer het ‘wonder der toneel' en zag daar op zo'n podium zijn toekomst.  Volleybalster Anne Buijs is één van de belangrijke speelsters van Oranje. Afgelopen zomer voelde ze zich opgebrand en besloot een rustpauze in te lassen*.* Ze ging mountainbiken, tennissen en nam motorrijlessen. Ze voelde zich een Bambi die door de heide rende. Inmiddels voelt ze zich herboren, is terug bij Oranje en gaat alles op alles zetten om zich komende maanden te plaatsen voor de Spelen in Parijs. Buijs groeide op in een volleybalnest - ook haar beide ouders waren internationals.

Vandaag te gast: Roeland Delrue, co-founder en CRO van Aikido. Deze startup uit Gent gaat snel: 1,5 jaar geleden bestonden ze nog niet en vandaag hebben ze al meer dan 20 medewerkers, 2 investeringsrondes achter de rug en misschien nog wel het meest opmerkelijke: ze haalden recent de hele VISMA groep binnen als klant. We praten over hun go-to-market strategie, die bestaat uit meerdere layers (PLG, sales assisted PLG en SLG), over het samenstellen van een team, over snelheid en over zijn persoonlijke lessons learned, ook uit zijn tijd in San Francisco, toen hij nog werkzaam was bij Showpad. Aikido: https://aikido.dev/ Leadinfo: https://leadinfo.com/saasbazen We Love SaaS: welovesaas.io/ Word lid van We Love SaaS We Love SaaS is de plaats waar SaaS ondernemers en professionals bij elkaar komen om te bouwen aan een succesvolle SaaS business. Stop met het wiel opnieuw uitvinden en krijg toegang tot de kennis en connecties die je nodig hebt om betere beslissingen te nemen. Je bent in een paar klikken lid en wordt direct onderdeel van het grootste SaaS ondernemersnetwerk van Nederland. Wat je krijgt: Korting op onze event, persoonlijke introducties, exclusieve deals bij partners en 1 keer per jaar een 1:1 coaching sessie met Johan de Wit, Jan Aleman of één van de andere coaches naar keuze, op een moment naar keuze. Word lid: welovesaas.io/membership/

Hessel Jan Smink ging in gesprek met Roeland Donker van Amazon. In een tijdperk waarin klantgerichtheid de sleutel is tot succes, streeft Amazon ernaar om niet alleen een leider te zijn, maar om het meest klantgerichte bedrijf op aarde te worden.   Roeland Donker, country manager Amazon.nl, schoof aan bij Hessel Jan Smink. Roeland's achtergrond is indrukwekkend, met studies in Nederlands burgerlijk recht, fiscaal recht en fiscale economie aan de Universiteit van Groningen.  In 2012 trad Roeland toe tot het team van Amazon en speelde hij een cruciale rol bij het lanceren van Amazon.nl in 2020. Zijn vroege jaren bij Amazon waren gericht op het opzetten van een EU-brede sourcing business en het beheren van Amazon's EU-exportactiviteiten, waarbij hij zich richtte op het wegnemen van barrières voor grensoverschrijdend winkelen voor Europese klanten. Met een team van honderden collega's richt Roeland zich nu dagelijks op het verbeteren van selectie, prijzen en gemak voor Nederlandse klanten. Hoe blijft Amazon zich inzetten om de verwachtingen van klanten te overtreffen en de lat voor klantgerichtheid steeds hoger te leggen? Van A tot Z Succesvol inspireert leiders om nog beter te worden in het managen of coachen van zichzelf en hun team. Met inspirerende studiogasten, eyeopeners en veel voorbeelden en ervaringen uit de praktijk. Er wordt ingegaan op wat succes nu eigenlijk is, wat betekent het voor je en hoe ga je er mee om?  Het programma is elke tweede donderdag van de maand tussen 11:00 en 12:00 uur te beluisteren op New Business Radio en wordt naderhand ook als podcast beschikbaar gesteld.

Dr. Ilana Braun and Dr. Eric Roeland join us on the ASCO Guidelines podcast to discuss the latest evidence-based recommendations on cannabis and cannabinoids in adults with cancer. They discuss nonjudgmental patient-clinician communication, the relatively narrow cancer-related indications for which there is actionable clinical evidence for cannabis and/or cannabinoids, and key information for adults with cancer and their clinicians. Dr. Braun and Dr. Roeland also review the limited evidence regarding cannabis and cannabinoid use in adults with cancer and the outstanding questions and importance of research in this area. Read the full guideline, “Cannabis and Cannabinoids in Adults with Cancer: ASCO Guideline” at www.asco.org/supportive-care-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/supportive-care-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  Brittany Harvey: Hello, and welcome to the ASCO Guidelines podcast, one of ASCO's podcast hosts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all of the shows, including this one, at asco.org/podcasts.  My name is Brittany Harvey, and today, I'm interviewing Dr. Ilana Braun from Dana-Farber Cancer Institute, and Dr. Eric Roeland from Oregon Health & Science University, co-chairs on “Cannabis and Cannabinoids in Adults with Cancer: ASCO Guideline.”   Thank you both for being here Dr. Braun and Dr. Roeland. Dr. Ilana Braun: Thanks so much for having us, Brittany. Dr. Eric Roeland: Thanks, Brittany. Brittany Harvey: Then, just before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensures that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Braun and Dr. Roeland, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. Then to jump into the content of this guideline, first, Dr. Roeland, could you give us an overview of both the scope and purpose of this guideline?  Dr. Eric Roeland: Sure, Brittany. I think it's important for everyone to recognize just how common the issue of cannabis or cannabinoid use is amongst people living with cancer. And I think clinicians in academia as well as through community sites, we are asked about the use of cannabis on a daily basis. And so our target audience is really to focus on clinicians providing care to adults with cancer, but also the health systems in which we work because this is a very complex issue, as well as the people living with cancer and their caregivers, as well as researchers dedicated to this field. Brittany Harvey: So as you mentioned, this is a complex issue, and I'd like to review the key recommendations of this guideline. This guideline provides recommendations across three clinical questions that the expert panel targeted. So, starting with the first question, what is recommended for patient-clinician communication regarding cannabis or cannabinoids?  Dr. Ilana Braun: Given the high prevalence of medicating with cannabis or cannabinoids that Eric references, somewhere in the neighborhood of 20% to over 40% of adults with cancer consume cannabis products, ASCO's guideline offers the following common-sense, good practice statement: In the clinic, providers should routinely and non-judgmentally inquire about cannabis consumption or consideration of cannabis, and either guide care or direct adults with cancer to appropriate resources. In other words, the guideline works to fully destigmatize this conversation. The guideline goes on to offer suggestions for taking a cannabinoid and cannabis history. This includes the goals of use, how the products are sourced, what formulations are being used (including the ratios of active ingredients like THC and CBD), the inactive ingredients (for instance coconut oil), whether it is herbal or synthetic, and whether the product is pharmaceutical grade or non-pharmaceutical grade. And then other questions like routes of administration, dosing schedules, perceived benefits and risks, and whether the products are being used adjunctively or as a replacement for standard treatments. It is also probably important to query potential contraindications, such as a history of cannabis use disorder or psychosis.  Brittany Harvey: Thank you for reviewing those good practice statements. Those are key for non-judgmental communication and taking an accurate and complete history.  So following those statements, the expert panel next addressed the question: Does use of cannabis and/or cannabinoids by adults improve cancer-directed treatment? What recommendations did the expert panel provide for this section? Dr. Eric Roeland: When we think about the use of cannabis or cannabinoids in treating the underlying cancer, it's incredibly important to recognize the excitement that patients and clinicians have around the potential promise. Much of this data is generated from preclinical models. However, when we're engaging patients consuming cannabis or cannabinoids to augment their cancer-directed treatment, we could find no evidence to support its use. And so we do not recommend that patients be using it to augment treatment, nor do we recommend that patients should be using it instead of their cancer-directed therapy. And I think this is a major challenge for multiple oncologists, where their patients may be using these with a goal of treating their cancer, and then present with very advanced cancer and/or multiple poorly controlled symptoms. Dr. Ilana Braun: And I think that there are some areas of particular concern. For instance, there were two oncologic cohort studies that suggest that cannabis, which we know is an immune modulator, may actually worsen immunotherapy outcomes. These outcomes included median time to progression and overall survival. There are obvious limitations of preliminary observational data, and we now need to gather prospective, gold-standard data. But for the time being, the guideline recommends that clinicians should advise against adults receiving immunotherapy from medicating or considering medicating with cannabis and cannabinoids. And then I think there are some additional reasons for concern. First of all, this type of therapy tends to be very expensive and not covered by insurance and there are some risks for drug-drug interactions, in terms of pharmacodynamic ones, Cannabis may exacerbate neuropsychiatric side effects of opioids and even benzodiazepines. In terms of pharmacokinetic drug-drug interactions, it's not a particularly risky substance, but there are three to be wary of in particular: warfarin, buprenorphine, and tacrolimus all have high-risk interactions with cannabinoid products.  Brittany Harvey: I appreciate you both for reviewing these recommendations and evidence regarding the use of cannabis and/or cannabinoids regarding cancer-directed treatment.   So then the last clinical question, Dr. Braun, what is recommended regarding use of cannabis and/or cannabinoids in managing cancer treatment-related toxicities and/or symptoms? Dr. Ilana Braun: The first thing to make clear is that high-quality clinical evidence evaluating the utility of cannabis and cannabinoids for adults with cancer is limited as Eric has said. The evidence that does exist weakly supports a practice of using cannabis and cannabinoids to address refractory chemotherapy-induced nausea and vomiting when standard treatments have failed. For other potential oncologic indications, like management of cancer-related pain, there is weak, negative, conflicting, or no evidence. But that being said, a 2017 monograph published by the National Academies of Science, Engineering, and Medicine concluded that there is substantial evidence that cannabis is an effective treatment for chronic non-cancer pain, and I'm sad to say, that chronic non-cancer pain happens too in adults with cancer. Brittany Harvey: Thank you for reviewing those recommendations as well.  So you've both touched on this a little bit in that patients are often asking clinicians for recommendations regarding cannabis and/or cannabinoids, but in your view, what is the importance of this guideline, and what should clinicians know as they discuss these recommendations with their patients? Dr. Eric Roeland: Probably one of the most important points is for clinicians to ask and to be open and to create a space where our patients are telling us about what they're using. I think we've all had patients that we've been surprised that have been using cannabis or cannabinoids in conjunction with other medications that may increase the risk of unwanted side effects or risks, including sedation or falls. I also find it challenging that many patients are receiving recommendations for the use of cannabis or cannabinoids directly from friends or family instead of through their medical providers. Therefore, I think one of the very first things is to just make sure that you're asking about it and then inquiring what the goal of their use is.  When we talk about the use of cannabis, we also need to recognize the difference between the available data that can guide us in evidence-based recommendations, as well as the enthusiasm and available access that patients have to cannabis that has really outpaced our ability to research it. So it's important to recognize these tensions that we're living with in clinic day-to-day. Brittany Harvey: Absolutely. Those points are key for clinicians as they discuss this complex issue with their patients.  Following that, how will these guideline recommendations affect adults with cancer? Dr. Ilana Braun: One really important takeaway from these guidelines is that they clearly state that cannabis and cannabinoids are medicinal, and for a medical community to clearly articulate this point is notable. I suspect they will provide encouragement, legitimacy, confidence, and even a script to oncology clinicians who were previously reticent to inquire, document, and provide clinical recommendations around non-pharmaceutical cannabis and cannabinoids. It may have a similar effect even at the institutional level in terms of supporting these practices. At the same time, I suspect they will encourage those who are recommending oncologic use of cannabinoids and cannabis for myriad cancer-related indications to adopt a more circumscribed approach. The reason I say this is that the cancer-related indications for which there is actionable clinical evidence at this time are quite narrow. So all this to say, I believe these guidelines will lead to greater transparency around cannabis decision-making in the clinic, as Eric mentions, but also lead to a possible narrowing of indications for which cannabis is clinically recommended.  Dr. Eric Roeland: Another major role of the use of these guidelines in clinical care is informing clinicians and patients about cannabis. Cannabis has been used by humans as a plant for thousands of years, and although it's a very complex plant with hundreds of parts, the two parts that researchers have studied most are delta nine-tetrahydrocannabinol, or THC, and cannabidiol, or CBD. In rough terms, THC can cause a high feeling, while CBD typically does not. And there are multiple types of products that have different ratios of THC and CBD. So it's critical for people to understand what those ratios are, how many milligrams of those things there are, as well as what are the programs within your region to measure or quantify what's actually in the products you're consuming. If a person with cancer medicates with cannabis, most oncologists would prefer that they use it by mouth, such as an edible, rather than inhaling or smoking cannabis given concerns about potential impact on lung function. One challenge when consuming cannabis by mouth is that it can take up to two hours to have its full effect. So patients should be very careful not to take too much or to stack their doses, which can cause sedation, confusion, and even increase the risk of falls. Whereas when patients are consuming cannabis by breathing in a smoke or vapor, they typically feel the effects almost right away, which is why patients sometimes prefer smoking or vaping as their preferred route of administration. Brittany Harvey: Understood. Definitely. We hope these guidelines provide key information and clarity for both adults with cancer and their clinicians.  So then, finally, you've both mentioned that there is limited evidence regarding cannabis and cannabinoid use in adults with cancer. So what are some of the outstanding questions regarding cannabis and cannabinoids in cancer care? Dr. Eric Roeland: Thanks, Brittany. I think the questions also align with priorities for future research, and we need to recognize that the lack of evidence aligns with some of the challenges of funding research in this space. However, ongoing future research priorities include what is the nature of healthcare disparities pertaining to medical cannabis use by adults with cancer, and what are effective means to address these disparities? We also wonder, what are the optimal strategies to maximize communication in the oncology clinic regarding medical cannabis and/or cannabinoid use? And when we're thinking about cannabis and/or cannabinoids for cancer treatment specifically, we still need to know do cannabis and/or cannabinoids possess clinically meaningful anticancer activity in humans. We also need to understand what are the drug-drug interactions with our standard-of-care cancer treatments, including cytotoxic chemotherapy, targeted therapy, immunotherapy, radiation, and combinations of all the above. We also are wondering what the effect of cannabis and/or cannabinoids on outcomes in adults with cancer receiving some of our newer therapies, including antibody-drug conjugates and some of our newer vaccine therapies.  Dr. Ilana Braun: I might add that collating the existing research as the guideline did is a very good first step and should serve to highlight where the gaps in knowledge lie. This guideline discusses some of the unique challenges to conducting cannabis and cannabinoid research, including limitations in funding source and study drug, red tape procedures, and issues around legalization. I believe it will take a group of highly determined and creative researchers to move the needle forward in this area, but we must. Brittany Harvey: Definitely. Thank you both so much for all of your work developing this guideline and creating these evidence-based recommendations. And thank you for taking the time to come on the podcast today and teach us all a little bit more about cannabis and cannabinoids in cancer care. And thank you for your time, Dr. Braun and Dr. Roeland.   Dr. Ilana Braun: Thanks so much, Brittany. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/supportive-care-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast, and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

 [music] ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. Greg Guthrie: Hi everyone, I'm Greg Guthrie, a member of ASCO's patient education content team, and I'll be your host for today's podcast. ASCO is the American Society of Clinical Oncology, and we're the world's leading professional organization for physicians and oncology professionals caring for people with cancer. Today we're going to be talking about what patients should know about cannabis, cannabinoids, and cancer. ASCO recently published a clinical practice guideline on cannabis and cannabinoids for adults with cancer. I'm happy to have 2 of the co-chairs from the committee that developed this guideline as our guests today. Dr. Ilana Braun is an associate professor at Harvard Medical School. Thanks for joining us, Dr. Braun. Dr. Ilana Braun: Thanks so much for having me. Greg Guthrie: It's a pleasure to have you here today. And Dr. Eric Roeland is an associate professor of medicine at Oregon Health and Science University. Welcome Dr. Roeland. Dr. Eric Roeland: Thanks, Greg. Greg Guthrie Great. So before we begin, I want to note that neither Dr. Braun nor Dr. Roeland have any relationships to disclose related to this podcast, but you can find their full disclosures in this podcast's show notes. So let's start with the fundamental question about this discussion, and that is what is a clinical practice guideline and how does it help guide cancer care? Dr. Roeland, can you start with this? Dr. Eric Roeland: Of course, yeah. A clinical practice guideline describes the best practices or what clinicians call the “standard of care” with regard to a specific topic. So this is kind of the blueprint that clinicians use to guide their practice when taking care of people with cancer. And the American Society of Clinical Oncology clinical practice guideline on the use of cannabis and/or cannabinoids summarizes the best available data collected specifically from humans in clinical trials, and we combined that with a multi-disciplinary panel of expert opinion. Greg Guthrie: Yeah, I think it's really important to always remember that best evidence comes from research in humans as well as from clinical expertise. So it's the best recommendations that we can have to support cancer care.   Dr. Eric Roeland: Greg, I also think it's very important to understand that there are different places that we gain knowledge in research. One is specifically when we are trying to figure out how a drug works, and we will test that in what we call “preclinical models,” which is usually within animals. And then, once we've determined safety and efficacy, then we start taking that information and approach studies in humans. And so when our listeners are learning about new data in the use of cannabis or cannabinoids, I encourage everyone to always stop and ask, is this data coming from the animals or is this from humans? Greg Guthrie: That's such an important point. And I think it's so essential to always look for that piece of evidence whenever you're reading about scientific advances. Alright, so let's take a moment to talk about what it means when we say cannabis and cannabinoids. Dr. Braun? Dr. Ilana Braun: Cannabis, which is better known as marijuana, is a plant that humans have turned to for thousands of years as a medicine, in manufacturing—for instance, in the making of rope­—and for enjoyment. It's often mistakenly viewed as having one main ingredient, tetrahydrocannabinol, or THC, but it actually has more than 300 ingredients that act in the body. Some of those ingredients are referred to as cannabinoids. There are 2 cannabinoids of greatest interest, THC, which I just mentioned, and CBD, cannabidiol. THC is responsible for the high feeling some people experience with cannabis. CBD is not. Currently in the U.S., some cannabis products containing these cannabinoids can be sourced at the pharmacy, others at cannabis dispensaries, and some through more informal means. Greg Guthrie: That's great. Thank you for that definition here as we continue this discussion. So what do people with cancer typically think cannabis and cannabinoids will do to help them? Dr. Roeland? Dr. Eric Roeland: Well, it's a great question, Greg, because in clinic, when patients and their loved ones express interest in either starting cannabis or cannabinoids or are currently using them, I always want to explore what their goal of use is. And interestingly, the goals of use are far-reaching. And I have heard everything from, to help with everything, to cure my cancer. And so it's incredibly important to understand why people are reaching towards these products, to understand what their goals are. If they're focused on using this to treat the underlying cancer, or instead of standard cancer therapies, we have grave concerns about this approach. And it may lead to worse outcomes of your cancer. However, if cannabis or cannabinoids are being used to help with controlling some symptoms during their cancer treatment, it may be helpful. And especially in one particular case where people have really bad nausea and vomiting that persists despite our best medicines to prevent it. Greg Guthrie: Thank you for that, Dr. Roeland. Dr. Braun, did you have anything to add? Dr. Ilana Braun: Maybe I will just point out that decisions on what to target with cannabis are often made through trial and error or in consultation with dispensaries, but not as much as I would prefer in consultation with clinical teams. Dr. Eric Roeland: So I would also add that it's incredibly important to bring these topics up with your clinical team because although cannabis and cannabinoids are considered safe by many because they're quote “natural,” it's important to recognize that they actually can interact with many of the other medications that you're already taking. For example, patients with cancer might be experiencing really bad pain or anxiety and taking things like opioids or benzodiazepines. And when you combine that with cannabis, it can prolong some of the effects of sedation or confusion. I'd also like to point out that this is not a time where people want to try cannabis for the first time, when they are weak and/or experiencing poor appetite and higher risk of falls. This is not the best time to be trying cannabis or cannabinoids without clear guidance from the clinical care team. Greg Guthrie: Do you find in writing this guideline and through your clinical experience that most people who are asking about cannabis and cannabinoids, that they already have been trying to use it or are considering it? Because there's a difference there, right? What goal are they looking for, and do they already have a predetermined assumption about what's going to happen with these? Dr. Eric Roeland: You know, Greg, as clinicians, we talk about a lot of hard stuff. We talk about challenges in terms of health care, access to care, cultural differences, financial toxicity. And it's so fascinating to me that we don't talk about something as simple as whether or not patients are using cannabis. And the reality is that when patients actually bring it up in clinic, I would say that most times they're already using it and are just simply asking for some advice on how to use it safely and effectively. So once I decided to lean in on this topic and create a space for patients and their loved ones to bring it up in clinic, I have found that it's brought up during most clinical encounters. Greg Guthrie: Fascinating. And so that's likely why the first recommendation of this guideline addresses the importance of communication between doctors and patients on this topic, correct? Dr. Eric Roeland: Yes, absolutely. I think that doctors are reticent to talk about this topic because of concerns around legal issues, which can be highly varied across the country. And Dr. Braun can speak to this more. Dr. Ilana Braun: Yeah, so in order to offer the very best care possible, I think that medical teams should know about all the medicines and supplements a person is taking. And this includes cannabis and cannabinoid products. Why? Well, because, as Dr. Roeland mentioned, cannabis and cannabinoids can sometimes decrease the effectiveness of some therapies that a person is on, likely including some cancer treatments, and they can also worsen side effects of other therapies. And then at the same time, cannabis and cannabinoids can be helpful in managing some symptoms of cancer and side effects of cancer treatment. So using them involves a careful weighing of risks and benefits. So for these reasons, oncology teams really do want to be part of the conversation as someone thinks through decisions around cannabis and cannabinoids. The ASCO guidelines encourage clinicians to be open and non-judgmental and welcome transparent discussions with patients about cannabis and cannabinoids. From there, clinicians should either assist personally if they feel qualified to do so, or refer a patient to high-quality information or an advisor with greater expertise. As for the types of information that might be helpful to share with the clinical team, a person with cancer who consumes cannabis or cannabinoids might wish to share why they're turning to cannabis, where they get their products, the active ingredients in them—so is it mainly THC or is it mainly CBD­—how they consume them, are they smoking, are they vaporizing, are they taking them by mouth, how often they consume them, what do they experience as the benefits and risks of using cannabis and cannabinoid products? Their clinicians may wish to know whether or not the cannabis products are being used as an add-on to standard treatments or whether they're being used in the place of standard treatments. And as Dr. Roeland suggested, they probably will want to know how much this practice is costing the patient each month and whether it is affordable. I think it's especially important to speak with your clinical team if you are considering using high-potency cannabis paste in an attempt to treat cancer itself. So not just manage symptoms, but actually treat cancer itself. The reason I think it's so important to share with your cancer team is that these cannabis pastes tend to have very, very high concentrations of THC and sometimes even CBD. And I think your cancer team can be helpful in thinking through the risks and benefits of that, helping to monitor side effects that might arise. It is commonly the case that people feel a little bit of confusion with very high doses of oral THC. Dr. Eric Roeland: I absolutely agree. And I think these high doses of cannabis products, they're often a tincture and delivered in a syringe. And it might look like black tar. And people are told to start off with the dosing of a grain of rice. But then they're told that the dose to treat their underlying cancer can be higher than a gram of cannabis a day. In some places it's a gram and a half. This is very high dosing, and it's going to cause people to feel extremely fatigued and increase the risk of falls and being sent to the emergency department. So I want to warn people about this practice in particular, because it can cause harm. We have no evidence that it actually works. Greg Guthrie: Thanks for that information there. I was wondering, is there a certain person on the health care team that patients should consider talking to, or anyone? Dr. Ilana Braun: I think anyone. Health care teams keep in close contact with each other. And so this kind of information would be shared amongst the team. So lots of cancer patients begin by sharing with their infusion nurse or their nurse practitioner. They don't even need to share necessarily with their oncologist as a first step. And anyone on the team should, after these guidelines, be able to access high-quality information through their institutions. Dr. Eric Roeland: And for those patients who might be in a location where they don't have access to an expert or don't have access to educational resources, I think one of the strengths of this current guideline is that we include an appendix, which clinicians can actually use as a 1-page handout for patients and caregivers to answer some of these most basic questions. For example, I think there's a lot of misunderstanding about how to take cannabis or cannabinoids. And what we do see is there's a big difference between ingesting orally an edible versus smoking or inhaling cannabis. And so, for example, cannabis when eaten by mouth can take up to 2 hours to have its peak effect. And unfortunately, what happens is that patients won't feel anything after several minutes to a half hour and then stack doses to the point that they get a much higher dose than they really need. And so we really encourage people to be aware of, if it's an edible, that it can take up to 2 hours. Whereas with your breathing it in or vaping, the effects can happen almost right away. But again, it's important to recognize that cannabis, whether it's smoked, vaped, or ingested, can be in your body for up to 12 hours and may even impact your ability to drive. So it's important that if you are going to use these tools in combination with the rest of your medicines, it's important to do it in a safe way. Another product that is now available, even over the counter at many grocery stores, is cannabidiol, or CBD. CBD in its pure form doesn't have the euphoria associated with products that contain more THC. Most people are using this as an anti-inflammatory, or targeting sleep. I would like to recognize that in our review of the literature, we discovered that high doses, meaning more than 300 milligrams of cannabidiol a day, actually changed the measurable enzyme levels of the liver. These enzyme levels in the liver are the same levels that we use to determine whether or not you can get your chemotherapy. So you want to make sure that you're not taking excessive doses of cannabidiol, meaning more than 300 milligrams a day, because you don't want your chemotherapy delayed because your liver enzymes might be elevated falsely from the use of high doses of cannabidiol. Greg Guthrie: That's great, Dr. Roeland. Thanks for adding that. As an additive or part of the cancer care plan, like with all medications, we need to be aware of what we're taking and report to our health care team so we can watch for interactions and potential side effects, right? So what are the rest of ASCO's guideline recommendations when it comes to this guideline for cannabis and cannabinoids? Dr. Ilana Braun: So as a committee, we submitted cannabis and cannabinoids to the same level of rigorous scrutiny that we would any other aspect of oncologic care. I can think of few other ways to validate this area of oncology science than to do so. And after an in-depth evaluation, the ASCO committee concluded that of all the reasons that a cancer patient might medicate with cannabis, the best scientific evidence supports using cannabis or cannabinoids to help with nausea and vomiting caused by cancer drugs when standard medications for nausea and vomiting don't work well enough. Of note, ASCO guidelines make clear that there isn't evidence to hang our hats on that cannabis and cannabinoids can treat cancer itself. What's more, early evidence suggests that cannabis and cannabinoids may actually worsen outcomes for people taking a cancer treatment called “immunotherapy.” Gold-standard clinical trials are necessary to confirm these worrisome findings, but for the time being, people on immunotherapy should probably best avoid cannabis and cannabinoids. I think Dr. Roeland and I and the rest of the committee have hope that more scientifically proven indications will emerge as cannabis research progresses. Dr. Eric Roeland: Dr. Braun has also pointed out to me that there's literature and evidence supporting the use of cannabis and/or cannabinoids for the management of chronic pain not related to cancer. And this has been actually described in other guidelines, and we need to recognize that our patients living with cancer often have chronic pain that may even predate their cancer experience. However, we do not have strong evidence to support that the use of cannabis and/or cannabinoids helps with cancer pain, which is a common reason that people are reaching for these medicines. Greg Guthrie: Great, thank you, Dr. Roeland. Thank you, Dr. Braun. So this guideline also recommends the use of cannabis or cannabinoids mainly within the setting of a clinical trial, and why is that? Dr. Eric Roeland: Well, Greg, I think it's incredibly important for people living with cancer and their loved ones to recognize that access to cannabis has far outpaced our ability to validate and study the best methods of using cannabis and cannabinoids in people living with cancer. Meaning access has far outpaced the science that supports its use. We also recognize that just because something is quote, “natural,” doesn't necessarily mean it is also safe, especially in combination with many of the drugs and cancer therapies that patients must receive while they're on treatment. Therefore, for those of you very frustrated by the lack of evidence to support the use of these medicines in people living with cancer, you should be the first in line to volunteer for any studies that help us collect prospective evidence to demonstrate not only safety but efficacy. I would also like to recognize how challenging it can be to perform these types of clinical trials based off of the formal designation by the federal government classifying this—cannabis and/or cannabinoids—as a Schedule 1 medicine, which creates multiple barriers for those clinical researchers who want to fully describe the safety and efficacy of these drugs. Therefore, if there is someone near you who is doing clinical research in this space, we greatly would appreciate your involvement in those clinical trials. Dr. Ilana Braun: I agree with Eric. By participating in clinical trials, a person is doing a very kind thing for others, helping to advance the science behind cannabis and cannabinoids. Only through this controlled, systematic testing will the medical community understand whether cannabis and cannabinoids can be helpful for indications beyond the chemotherapy-related nausea and vomiting. And we as a society need to understand whether cannabis or cannabinoids can be helpful for cancer pain, for cancer-related poor appetite, to name just a few. These clinical trials will help us move the field forward. And in terms of personal benefit, I could imagine that clinical trials might offer someone more quality-assured cannabis products, more scientifically based dosing guidelines, careful clinical observation should side effects present, and potentially efficacy. But of course there are no guarantees. That's why we're doing the trial. Greg Guthrie: Thanks, Dr. Braun. Yeah, clinical trials are a safe way to grow our knowledge in cancer care and treatment. And definitely, as Dr. Roeland said, if we don't have evidence, the evidence in this current guideline to support recommendations, then the only way we can truly find that is by participating in clinical trials. And so I would just note that if you're interested in participating in a clinical trial, talk to a member of your health care team. And there are a number of online resources, such as ClinicalTrials.gov, where people can look for research. That's how we advance the science. So is there anything else people with cancer should know about using cannabis or cannabinoids during cancer treatment? Dr. Eric Roeland: One key message I think for our listeners is to recognize that people have varying tolerances to this class of medicines. And what I frequently observe is that an older patient is offered an edible by their well-intentioned children who want their mom or dad to start eating more in the setting of their cancer. Unfortunately, I've experienced taking care of people that have had side effects associated with the use of cannabis or cannabinoids leading to even emergency department visits and hospitalizations. And although these products are overall very safe and you cannot quote “overdose” on them or stop breathing because you're taking too much cannabis, it can be very uncomfortable to feel very confused and unable to stand or walk. That can be prolonged for many people, especially those who feel especially weak during their cancer therapy. And our loved ones mean well, but sometimes the advice that they're providing could actually cause harm. And sadly, I've had many children of patients who have felt incredibly awful after their loved one had a side effect from these medicines, which actually delayed their cancer care. Greg Guthrie: Excellent point, Dr. Roeland, thank you for that. Dr. Braun, any final notes? Dr. Ilana Braun: Yeah, so following on Dr. Roeland's thoughts, I would also add that it's important to think about safe storage for such products, particularly if there are children or pets in the home. Cannabis products sometimes look like medicine and sometimes look like candy or baked goods. And so it's important to store them out of the reach of minors and pets. And the last thing I'll emphasize is this: if you are living with cancer and medicating or thinking of medicating with cannabis or cannabinoids, please consider sharing this information with your clinicians so that they can help you strategize about an optimal course. Dr. Eric Roeland: I would like to take a moment to thank the American Society of Clinical Oncology for recognizing that we need to address this important need for people living with cancer. And rather than ignore something that's happening every day in the clinic, ASCO chose to convene a panel of experts and coalesce the data and try to figure out what best practices are in this space. And to that, I am very proud to be a member of ASCO who chooses to lean into these difficult topics rather than run away. I would also say this is a keen opportunity for everyone to advocate for more research in this space. Because talented folks like Dr. Braun, who want to do research in this space, need advocates, need participants, and need funding to fund this type of research. So again, kudos to ASCO, the members of the panel, and, of course, our patients. Dr. Ilana Braun: Thank you, Eric, for saying that. I am so grateful to have been a part of this really cutting-edge process. And I think that clinical guidelines will help to de-stigmatize cannabis care in a meaningful way in the oncology clinic. Greg Guthrie: This has been great. Thanks, Dr. Braun. Thanks, Dr. Roeland. If I can interject, I think one of my biggest takeaways here is every patient, caregiver, if they are or are considering cannabis or cannabinoids, the biggest question is to ask, why am I choosing this? And then to find a member of their health care team and talk to them about that. And that's how we protect each other's health and we ensure the best results possible for everyone. So I want to thank you both so much for this engaging discussion. Dr. Braun, Dr. Roeland, thanks for joining us today. And our listeners, if you'd like to learn more about this guideline, please visit www.asco.org/guidelines. Thanks so much for joining us today, and be well. ASCO: Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate. [music]

In this episode, Clare is joined by Lilian Roeland who has been living in Spain, for decades. She was raised in The Netherlands and has also lived in South Africa and plans to live in Canada. She went on holiday to Spain, fell in love with the country and made it her home.  Lilian talks about understanding cultural differences and how not taking them into account enough impacts your life. She also explains how she managed being separated from friends and family and what she did when her father fell sick. Lilian also shares her experience of living in South Africa working to make the life of young people easier. KEY TAKEAWAYS Taking opportunities is the best way to learn, expand your horizons and live a full life. Having a safe home to go back to or a backup plan is essential. It enables you to be brave and try things. There are many cultural differences in Spain despite them being in Europe. Never ignore cultural differences. Try to accept and adapt to them. Life in Spain is different but good. Longer days and a relaxed social environment are just two examples. In Spain, knowing the right people helps to speed bureaucracy up. Racism is still an issue in Spain, mainly with the older generation. When trying to help people in other countries ask them what they need, don´t assume you know. The European way of doing things is not a good fit everywhere. When returning to your own country after spending many years abroad you will experience a culture shock. You and your home country have changed. So, you will need to adapt. BEST MOMENTS ‘I went out in the world free to see what would happen. ´ ‘Administration is a lot slower.' ‘Don´t just assume that you will know better, there are always different options.'   ABOUT THE HOST – CLARE KAY Clare has moved countries many times throughout her life, from China to Taiwan, Nigeria, Zambia, and the USA. She has also travelled the world for various businesses and now wishes to impart her advice to others to save them time, money, and energy.  Clare follows three principles central to her endeavours. First, she looks outward internationally, working with people overseas or of different nationalities. Second, she is obsessed with communication, having learned French, German and Mandarin Chinese. She also teaches English and works as an editor for others' work. Clare is passionate about making a difference through her coaching in the world of personal development.  CONTACT METHOD www.kayproofreading.com  www.linkedin.com/in/clarekay   https://www.facebook.com/KayProofreading Podcast Description When you move for a new job, to live with someone after a long-distance relationship or to explore the benefits of a new lifestyle, moving countries occurs as an opportunity, but it still might be a bumpy ride. Moving Countries 101 presents a paradox of moving to a new destination, but it being all about the journey: the ongoing experience of having moved countries.    Clare and her guests share the human stories of an ancient undertaking in modern times. Moving countries prompts change, and change provokes being unsettled emotionally, physically, mentally, and spiritually. On all these fronts, moving countries promotes observation, opportunity, and discovery.

It's getting closer to the end of the year, which means that it's time for our next episode of Mirrors and Windows. This year, founding member and current director Roeland Paardekooper chats with Matilda Siebrecht, who will be taking over the role of director in January. Together, they talk about what's happened in 2023 - from the conference in Turun to this year's EXARC award winners - and look ahead to what's coming in 2024 - such as the culmination of projects such as ReTold and TELT. They also look even further back, with Roeland sharing some of his experiences and stories from his time in EXARC (although he insists he wasn't sitting in a rocking chair by the fire during the recording!). And of course, they also look further ahead, as Matilda shares some of her plans and ideas for the future of EXARC.Support the show

Hans Wensveen en zijn vrouw Marleen zijn aangesloten bij de Nederlandse Caravan Club. Een zestal leden van deze vereniging organiseerden afgelopen oktober een kampeerweekend. Hans was voor dit weekend, samen met zijn vrouw en andere leden, met 37 caravans neergestreken op camping Kampeerhoeve Bussloo in Wilp. In dat weekend waarbij men, en dat kon je vorige week horen, een rondleiding om, rond en in het kasteel Ter Horst in Loenen kreeg. In datzelfde kasteel vond er 's avonds ook een concert plaats met harp en dwarsfluit. In deze podcast zal je daar een deel van te horen krijgen. Voordat het duo Tickled Pink met hun muziek begint spreekt Hans Wensveen nog even met organisator Roeland die het duo heeft gecontracteerd.

Als je schouder versleten is, niet meer goed beweegt of pijn doet kan een schouderprothese een oplossing zijn. Het is een kunstgewricht dat een deel van je schouder vervangt. Luister naar deze Tergooi Podcast om er alles over te weten. Een greep uit de vragen waarop orthopedisch chirurg Roeland Riedijk antwoord geeft in deze podcast: Welke behandelingen zijn mogelijk bij schouderklachten? Wanneer kom je in aanmerking voor een schouderprothese? Hoe verloopt de operatieve ingreep? Hoe lang duurt het herstel? Gaat een schouderprothese lang mee? Kan je alles weer doen met een schouderprothese?

“The push coming from the private sector is very palpable.”How can governments and industry work together to navigate the green transition? Should there be a proper price on carbon? What will the energy mix look like in a decades time?In this week's episode of the FridayFix, Powerscourt's Peter Ogden sits down with Roeland Baan, President and CEO of Topsoe to get the answers to all of this and more.With COP28 just around the corner, Roeland explains how Topsoe is leading the charge in developing technological solutions to support the green transition in some of the hardest to crack sectors, and shares his hopes and expectations for this year's climate forum in Dubai. 

Werkgeluk: het is de optelsom van werktevredenheid, werkplezier, werkengagement en werkbetekenis. Uit het onderzoek dat Travvant samen met Indiville liet uitvoeren blijkt dat werktevredenheid en bevlogenheid significant gedaald zijn tegenover 10 jaar geleden. We zijn dus collectief minder tevreden en minder bevlogen. Hoe zorgen we ervoor dat mensen weer ‘fluitend' naar het werk gaan? Door in te zetten op ‘high quality motivatie', lees ik in People First, het boek dat Roeland van Dessel, gedelegeerd bestuurder van Travvant heeft uitgebracht in 2022. High quality motivatie is een van de 8 sleutels die in het boek naar voor geschoven wordt om te komen tot een futureproof arbeidsmarkt. Verloning en extralegale voordelen zijn hun glans verloren en zouden er vooral toe leiden dat mensen zich gevangen voelen in een gouden kooi, lees ik. Daar wil ik het in deze podcast graag over hebben. Samen met Marijke Jonckers, outplacement coach en loopbaancoach bij Travvant en met Kris De Schutter, partner bij Loyens & Loeff. Veel kijk- en luisterplezier!+++Honger naar meer? SCHRIJF JE IN VOOR DE NIEUWSBRIEF LEES DE ARTIKELS ABONNEER JE OP HET TIJDSCHRIFTAnd don't forget: it's a great time to be in HR!+++Opgenomen op de #ZigZagHR Kantoorboot

It requires elite athlete skills to do what Roeland did.It's just not as easily spotted.Most people at 200kg would probably not even allow the thought of ever running a half marathon. Yet, Roeland somehow believed it was possible.Patiently he dedicated himself to the journey of weight loss and eventually to training for his first half marathon.This is a podcast where we cover:○ How to lose weight and train sustainably○ The power of a humble, curious, and patient mindset○ What's even much more important than weight loss to RoelandIt's inspiring. And I hope to have many more of these elite athletes in disguise on the podcast.Let me know if you know one of these superheroes. Instagram

Drie jaar geleden schreef Niels Meijssen op LinkedIn de frustratie van hem af toen hij las dat Booking.com coronasteun aanvroeg: ‘Waarom heeft een bedrijf dat vorig jaar nog 5 miljard winst maakte, 65 miljoen staatssteun van de belastingbetalers nodig?'. Zijn post kreeg bijval, waarop Niels besloot om een eerlijke bookingssite op te richten. Drie jaar zijn verstreken sinds het begin van 'zijn' Moonback en nu is het mogelijk om via dit platform naar tientallen steden in Europa te reizen, zonder afleiding en met eerlijke zoekresultaten. Hij besloot om met René Bego een samenwerking aan te gaan: Hotelboekingssite Moonback en Time to Momo, bekend van de stedengidsen, bundelen hun krachten en gaan samen verder onder de naam Time to Momo. Met deze samenwerking willen zij hun positie vergroten in de reiswereld. Jonathan van Noord ging met hen in gesprek over de ontwikkeling van hun platform en welke kansen er nog in het verschiet liggen. Naast Niels en René kwamen er gasten van de Nationale Ondernemersprijs langs: Marco Arts, COO bij Carbyon;  en Roeland van Delden, oprichter van Leadax.  En 'Ever Given'... zegt die naam u wat? Het is de naam van het schip dat in maart 2021 in totaal zes dagen vast lag in het Suezkanaal. Het gevolg? De wereldwijde scheepvaart kwam tot stilstand en handelsstromen liepen volledig in de war. De blokkade liet daarnaast pijnlijk zien hoe afhankelijk sommige bedrijven waren en misschien nog wel zijn van fragiele aanvoerlijnen. Zijn er opties? En hoe pak je die als ondernemer aan? Arjan van der Woning, managing director bij logistiekdienstverlener Toll Global Forwarding vertelde hoe dit precies werkt.  In de uitzending was er ook een De Ondernemer Pitch: Nic Jooste van Selati was te gast en pitchte zijn bijzonder smaakvolle plan. Tot slot vertelde ondernemer en coach Ralph van Dam over de consequenties van verzuim, want daarover gaan ondernemers pas nadenken als er een medewerker uitvalt. Vaak is dat al te laat. Kortom: een bomvolle show. Presentatie: Jonathan van Noord

Drie jaar geleden schreef Niels Meijssen op LinkedIn de frustratie van hem af toen hij las dat Booking.com coronasteun aanvroeg: ‘Waarom heeft een bedrijf dat vorig jaar nog 5 miljard winst maakte, 65 miljoen staatssteun van de belastingbetalers nodig?'. Zijn post kreeg bijval, waarop Niels besloot om een eerlijke bookingssite op te richten. Drie jaar zijn verstreken sinds het begin van 'zijn' Moonback en nu is het mogelijk om via dit platform naar tientallen steden in Europa te reizen, zonder afleiding en met eerlijke zoekresultaten. Hij besloot om met René Bego een samenwerking aan te gaan: Hotelboekingssite Moonback en Time to Momo, bekend van de stedengidsen, bundelen hun krachten en gaan samen verder onder de naam Time to Momo. Met deze samenwerking willen zij hun positie vergroten in de reiswereld. Jonathan van Noord ging met hen in gesprek over de ontwikkeling van hun platform en welke kansen er nog in het verschiet liggen. Naast Niels en René kwamen er gasten van de Nationale Ondernemersprijs langs: Marco Arts, COO bij Carbyon;  en Roeland van Delden, oprichter van Leadax.  En 'Ever Given'... zegt die naam u wat? Het is de naam van het schip dat in maart 2021 in totaal zes dagen vast lag in het Suezkanaal. Het gevolg? De wereldwijde scheepvaart kwam tot stilstand en handelsstromen liepen volledig in de war. De blokkade liet daarnaast pijnlijk zien hoe afhankelijk sommige bedrijven waren en misschien nog wel zijn van fragiele aanvoerlijnen. Zijn er opties? En hoe pak je die als ondernemer aan? Arjan van der Woning, managing director bij logistiekdienstverlener Toll Global Forwarding vertelde hoe dit precies werkt.  In de uitzending was er ook een De Ondernemer Pitch: Nic Jooste van Selati was te gast en pitchte zijn bijzonder smaakvolle plan. Tot slot vertelde ondernemer en coach Ralph van Dam over de consequenties van verzuim, want daarover gaan ondernemers pas nadenken als er een medewerker uitvalt. Vaak is dat al te laat. Kortom: een bomvolle show. Presentatie: Jonathan van Noord

Hoe maak je een vrachtwagen op maat en zijn die grote trucks al klaar voor een emissieloze toekomst of duurt dat nog wel even? Roeland van der Woude, topman van vrachtwagenbouwer GINAF is te gast in BNR Zakendoen.  Macro met Boot  Elke dag een intrigerende gedachtewisseling over de stand van de macro-economie. Op maandag en vrijdag gaat presentator Thomas van Zijl in gesprek met econoom Arnoud Boot, de rest van de week praat Van Zijl met econoom Edin Mujagić.  Economenpanel  Achterblijvende koopkracht, toenemende armoede en een oplopend begrotingstekort. Het kabinet moet alle zeilen bijzetten om deze problemen te lijf te gaan, blijkt uit nieuwe ramingen van het Centraal Planbureau. En: Wordt Duitsland na vijfentwintig jaar weer ‘de zieke man van Europa'?. Dat en meer bespreken we om 13.00 in het Economenpanel met Menno Middeldorp (hoofd bij RaboResearch) en Edin Mujagic (Hoofdeconoom OHV Vermogensbeheer).  Luister l  Economenpanel Inzichtgesprek   Authentiek leiderschap is niet voor iedereen weggelegd en al helemaal niet voor vrouwen. Leidinggevende vrouwen of vrouwen met die ambitite hebben last van stereotyperende beelden: of ze zijn té mannelijk óf ze zijn geen échte leiders.   Bij ons te gast is Caroline Glasbergen schrijfster van het boek New Female Leader en oprichter van New Female Leaders.  Zakenpartner  Na een impulsieve verhuizing naar Amsterdam, kwam ze terecht in een studieperiode waarin ze van alles wat heeft geprobeerd. Maar na een lange carièrre bij KLM, nam ze toch een vogelvlucht naar het ondernemerschap, en besloot ze voor zichzelf te beginnen. De zakenpartner van deze week is Madeleine Braun, medeoprichter van Flox Flowers.  Contact & Abonneren  BNR Zakendoen zendt elke werkdag live uit van 12:00 tot 14:30 uur. Je kunt de redactie bereiken via e-mail en Twitter.  Abonneren op de podcast van BNR Zakendoen kan via bnr.nl/zakendoen, of via Apple Podcast en Spotify. See omnystudio.com/listener for privacy information.

Is vrachtwagenbouwer GINAF voorbereid op een toekomst waarin vrachtwagens emissieloos moeten zijn? In ‘De top van Nederland' een uitgebreid gesprek met Roeland van der Woude, topman van vrachtwagenbouwer GINAF  Abonneer je op de podcast  Ga naar ‘De top van Nederland' en abonneer je op de podcast, ook te beluisteren via Apple Podcast en Spotify. See omnystudio.com/listener for privacy information.

In deze podcast bespreken Wouter koppert van Vibber en Roeland Jacobse van Multivalue samen met Paul de Vries de uitdagingen en mogelijkheden in de autoverkoop. De focus van het gesprek ligt op de verbetering van de klantbeleving in de online automotive sector. Ze benadrukken de cruciale rol van coaching en ontwikkeling van medewerkers, met name salesmanagers, om een positieve klantbeleving te realiseren. Mystery Shopping en auditsCoppert licht toe dat Vibber een consultancybureau is dat zich richt op organisatieontwikkeling, rendementsverbeteringen, digitalisering en audits. Hij onderstreept het belang van kwaliteit en klantbeleving in de automotive sector en illustreert hoe audits en klantbelevingsonderzoeken kunnen bijdragen aan het optimaliseren van bedrijfsprocessen. Roeland van Multivalue legt uit dat hun bedrijf focust op het optimaliseren van de customer experience in de automotive sector. Hierbij evolueert hun aanpak van mystery-shopping naar coaching en het bieden van praktische feedback aan verkopers. De salesmanager In het gesprek wordt het belang van competent salesmanagement en effectieve coaching benadrukt. De gasten en de presentator wijzen op het belang van het kijken naar het geheel van processen binnen het bedrijf, niet alleen naar individuele prestaties van verkopers. Ze bespreken ook hoe tools en systemen kunnen bijdragen aan het verbeteren van de sales funnel en personeelsveranderingen kunnen opvangen. Uit hun lopende klantbelevingsonderzoek blijkt dat ongeveer 30% van de online leads geen opvolging krijgt, wat de discussie aanzwengelt over het belang van gedegen klantenservice en opvolging. Het gesprek wordt afgerond met de aankondiging van de CX Automotive Awards, een evenement dat bedrijven die uitblinken in klantbeleving in de automotive sector wil erkennen en belonen. Heren, bedankt voor jullie komst naar de podcaststudio. Luisteraars bedankt voor het luisteren. Volgende week is er weer een nieuwe podcast met een nieuwe gast.  Deze Podcast wordt mede mogelijk gemaakt door: Marktplaats, 2dehands.be, UCC, Calldrip, CARMEN Automotive BDC, Findio en Vinacles Marktplaats is met ruim 7.3 miljoen unieke bezoekers per maand al jaren een van de populairste sites van Nederland. Per dag worden rond 350.000 nieuwe advertenties op de site geplaatst. Particuliere en zakelijke aanbieders zorgen voor een groot en gevarieerd tweedehands en nieuw aanbod. Marktplaats is de plaats met de hoogste kans om een betrouwbare tweedehandse auto succesvol te (ver)kopen tegen een goede prijs. Waarom kiezen voor Calldrip? Calldrip is een succesvol leadopvolgings systeem dat zijn oorsprong heeft in de Verenigde Staten en dankzij #DCDW nu ook in Nederland en België beschikbaar is. Het systeem is vooral geschikt voor importeurs en grote dealerholdings die ervoor kiezen de leadopvolging bij de verkopers te leggen. Calldrip is de ideale tool om verkopers te ondersteunen bij leadopvolging en tot maximale conversie te komen. Waarom kiezen voor UCC? UCC: Steeds meer collega's gebruiken Used Car Controller. Taxeren, calculeren, publiceren of auto's verhandelen met je persoonlijke handelsplatform? Met 1 abonnement geeft Used Car Controller je controle over alle kritische gebruikte auto processen. Zo maakt Used Car Controller je tot de beste in je vak! Waarom kiezen voor Vinacles? Vinacles biedt verschillende diensten met als doel uw automotive gerelateerde werkprocessen zo eenvoudig en overzichtelijk mogelijk te maken. Door middel van de verschillende applicaties en diensten faciliteert Vinacles in de complete optimalisatie van uw bedrijfsproces op één platform. Denk hierbij aan Garage en Fleet-managementsystemen, RDW-diensten, Occasion remarketing, Voertuigdata en Import- en export.  

Voor de tweede keer een special in het teken van kinderseries van vroeger! Roeland, Lizzy, Martin en Sander duiken nog een keer in de wondere wereld van de series die vroeger de tv beheersten. James Bond junior, Thunderbirds, Benjamin Ben, de ark van Stekeltje, en meer! --- Send in a voice message: https://podcasters.spotify.com/pod/show/terugspoelen/message

   I took the bait and checked out some network coverage today and what do you know, they are all over the leaked audio of Donald Trump talking to a couple book writers and staffers.  Shocker of all shockers, it's what they left out that gives context to this event.    Roeland Park's new mayor is putting in rules for gender identity in the city's employee handbook.  He may have his heart in the right place, but he's so wrong about how this will play out.    LSU fans go wild as their team routs Florida in the final game of the College World Series.  A lot of fan bases say it... but LSU fans may be the greatest of them all.    An Eagles defensive end is still making insanely lame excuses for losing to the Chiefs in the Super Bowl and the Jets are bracing to be told they have to be on Hard Knocks this year.

On this week's PreserveCast join us as we talk with Dr. Roeland Paardekooper about EXARC, a global network of professionals active in archaeological open-air museums and experimental archaeology, ancient technology, and interpretation. Dr. Paardekooper will talk us through this unique field of study and how you can learn traditional skills by engaging with EXARC.   Dr. Roeland Paardekooper serves as the Director & EXARC Journal Executive Editor, and has expertise in Archaeological Open-Air Museums and Experimental Archaeology. Dr Paardekooper graduated from Universiteit Leiden (NL) with his BA & MA, and from the University of Exeter (UK) with a PhD. He was awarded the Museum Horizon Award in 2015 and the Knight in the Order of Orange-Nassau in 2012.   Learn More: https://exarc.net/ Guedelon: https://www.guedelon.fr Colonial Williamsburg: https://www.colonialwilliamsburg. org/ Lejre Land of Legends: https://sagnlandet. dk    

Niet alleen mensen met lage inkomens, maar ook opvallend veel mensen met hogere inkomens kloppen aan voor schuldhulp bij hun gemeente. Zorgelijk, vindt branchevereniging voor schuldhulpverlening NVVK. "We zien echt een nieuwe groep mensen die de eindjes niet meer aan elkaar kan knopen", stelt Auke Schouwstra. Ook opvallend veel ondernemers hebben zich vorig jaar voor schuldhulpverlening aangemeld. Daarom is ons breekijzer: 'Mensen met een hoger inkomen en schulden moeten hun eigen broek ophouden.' Verder hebben we het over De Nederlandse Bank die een compromis heeft gesloten over witwastoezicht met andere banken. Zo hoeven banken alleen nog hun meest risicovolle klanten streng te controleren. Dat betekent een einde aan alle belemmerende vragen die ze aan hun klanten moeten stellen. Maar als je eenmaal onder dat vergrootglas ligt hebben banken het recht ‘hun meest intensieve controles uit te voeren'.  Ook bespreken we dat GroenLinks-Statenlid Debora Fernald gisteren niet op haar eigen partij stemde, maar koos voor Volt. Daardoor heeft GroenLinks nu een zetel minder in de Eerste Kamer. Toen de linkse partij daar achter kwam is ze pardoes uit de fractie gezet.  In ons panel: Sophie Koppejan, student politieke communicatie en media-analist   Youssef Kobo, directeur A Seat at a Table Onze Breekijzer-expert: Roeland van Geuns, Emeritus lector Armoede Interventies aan de Hogeschool van Amsterdam  Over BREEKT In BNR Breekt breken we de sleur van jouw ochtend met een goede discussie over het nieuws. Dat doen we met opkomende opiniemakers en deskundigen. BNR Breekt is het meest verfrissende opinieprogramma van de Nederlandse radio.  Maandag tot en met donderdag van 11:00 tot 12:00 Presentatie: Iwan Verrips Vrijdag is er Breekt Politiek van 11.00 tot 12.00 Presentatie: Nina van den DungenSee omnystudio.com/listener for privacy information.

Roeland Vos drives Belmond up the luxury track.

May 22: Today on the Conference channel, it's an Interview in Action live from HIMSS 2023 with Roeland Pelgrims, CEO of Nobi BV, and Sarah Thomas, CEO at MezTal and Venture Partner at AgeTech Capital. How does Nobi's technology improve the lives of the elderly by combining functionality and design? How do their smart lamps detect falls using optical sensors and AI analysis? How does their technology enhance the care provided in nursing homes and memory care facilities? How did Nobi take their target audience into account when designing the look and feel of their smart lamp?Join us on June 8 at 1PM ET for our webinar: 'The Future of Care Spaces' This webinar will focus on the latest healthcare technologies and solutions transforming care spaces in America. Care spaces can include hospitals, clinics, and at-home treatments where advanced technologies can enable better workflows, treatments, and patient outcomes. Register Here: https://thisweekhealth.com/future-of-care-spaces/Subscribe: This Week HealthTwitter: This Week HealthLinkedIn: Week HealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer

Amazon kwam drie jaar geleden naar Nederland, maar heeft hier nog niet zo snel marktaandeel veroverd als in veel andere landen wel gebeurde. Wat maakt de Nederlandse markt anders voor de webwinkel gigant en waar liggen de potentiële groeikansen? Roeland Donker, countrymanager Nederland van Amazon is te gast in BNR Zakendoen.  Macro met Mujagić  Elke dag een intrigerende gedachtewisseling over de stand van de macro-economie. Op maandag en vrijdag gaat presentator Thomas van Zijl in gesprek met econoom Arnoud Boot, de rest van de week praat Van Zijl met econoom Edin Mujagić.  Beleggerspanel  Roy Jakobs trotseert zijn eerste jaarvergadering als topman van Philips. Wanneer komt er duidelijkheid over de kosten van de slaapapneu-affaire? En: Warren Buffett geeft ook op 92-jarige leeftijd nog les aan zijn aandeelhouders. Maar bij de jaarvergadering staan zijn opvolgers steeds meer in de schijnwerpers. Dat en meer bespreken we om 13.00 in het beleggerspanel met:  - Martine Hafkamp, oprichter Fintessa Vermogensbeheer  - Thijs Knaap, hoofdeconoom APG Luister | Beleggerspanel Yoghurt Barn  YB, het voormalige Yoghurt Barn, heeft de deuren van zijn horecatak gesloten. Daarmee laat YB de Barns achter zich en gaan zij verder als leverancier van plantaardige producten. Te gast is Wouter Staal, oprichter en mede-eigenaar van de YB-keten  Zakenpartner  Na een studie politicologie en bestuurskunde aan de Vrije Universiteit van Amsterdam wilde ze graag de eerste vrouwelijke premier van Nederland worden. Deze ambitie heeft ze laten varen, maar voorzitten en besturen doet ze nog steeds bij 8 verschillende partijen, daarnaast is ze haar eigen bedrijf gestart waarin ze vrouwen ondersteund met gezondsheidsklachten door de overgang.   Te gast is Wieneke Groot van Buro Vitale Vrouw  Contact & Abonneren  BNR Zakendoen zendt elke werkdag live uit van 12:00 tot 14:30 uur. Je kunt de redactie bereiken via e-mail en Twitter. Abonneren op de podcast van BNR Zakendoen kan via bnr.nl/zakendoen, of via Apple Podcast en Spotify.See omnystudio.com/listener for privacy information.

Hoe zorgt Amazon voor goede werkomstandigheden in zijn Nederlandse sorteercentrum na eerdere kritiek in het buitenland? In ‘De Top van Nederland' een uitgebreid gesprek met Roeland Donker, countrymanager Nederland van Amazon.  Abonneer je op de podcast  Ga naar ‘De top van Nederland' en abonneer je op de podcast, ook te beluisteren via Apple Podcast en Spotify. See omnystudio.com/listener for privacy information.

Hoe je een heldere boodschap krijgt waar je hele team achter staat in 1 dag!Wekelijks ontvangen wij reacties of spreken wij mensen die worstelen met het creëren van een heldere boodschap en bang zijn dan hun team er niet achter staat. In deze podcast vertellen Daan en Roeland meer over de StoryBrand Private Marketing Workshop en krijg je antwoord op de volgende vragen:Wat is een StoryBrand Private Marketing Workshop?Voor wie is de workshop bedoeld?Wat is het verschil tussen de Private Marketing Workshop en de StoryBrand 2-daagse Marketing Workshop?Wat zijn de redenen waarom iemand voor de Private Workshop kiest?Wat betekent dit voor de afdeling Sales?Op welke locatie vinden deze workshops plaats?Wat heb je aan het einde van de workshop bereikt?Welke mensen uit het team kun je hiervoor uitnodigen?Wat is de investering?Meer informatie over StoryBrandStoryBrand Podcast https://storybrand.nl/podcast/StoryBrand boek https://storybrand.nl/boek/Private Workshop https://storybrand.nl/private-workshop/2 daagse StoryBrand Marketing Workshop https://storybrand.nlStoryBrand Online training https://storybrand.nl/online-training/StoryBrand Gids Certificering https://storybrand.nl/gids-certificering/

In deze podcast hoor je de trends en ontwikkelingen voor 2023!Daan en Roeland zijn in gesprek over de 10 trends en ontwikkelingen die zij zien in marketing & sales bij het bouwen van een bedrijf online en offline.1. Clarity always winsBetere marketing begint bij je boodschap. Zorg dat je bekend staat om 1 ding.En je boodschap super duidelijk is.2. Trusted AdvisorDat doe je door te zorgen dat je niet meer een van de velen bent, maar er boven gaat hangen en open, eerlijk en transparant communiceert. 3. Content is kingMensen zoeken online naar informatie, zorg dat dit op je website te vinden is en je vragen van de klant beantwoord worden.4. Eerlijk duurt het langstAls mensen niet meer hoeven te zoeken naar antwoorden op hun vragen en je geeft de informatie vooraf en bent open en transparant in je communicatie.5. Buyers journeyDe buyers journey is nog meer online dan ooit tevoren. De oriëntatie begint online buiten het gezichtsveld van de ondernemer.6. De combi tussen offline en online wordt nog belangrijkerMensen hebben behoefte aan verbinding.7. A.I. wordt geïntegreerd in de marketingmixDit is niet meer iets van de toekomst maar over het hier en nu.8. Sales en Marketing UnifiedAllignment dekt niet meer de lading. Hoe kun je marketing bedrijven vanuit je sales. 9. Meer kanalen niet minderJe hebt meer kanalen nodig om hetzelfde resultaat te bereiken. 10. Laat de data het werk doenJe hebt data nodig om te zien wat werkt.Op een succesvol 2023!Wil je starten met een heldere boodschap en een 5 stappen marketingplan wat wel werkt ga dan naarwww.storybrand.nl

The food we eat is essential, especially in postpartum. Dr. Jennifer Roelands, OB-GYN, dives into just how important nutrition is and how it relates to postpartum depression, anxiety, gut health, and more. She also touches on the importance of self-advocacy and finding the proper care provider for your needs. 033 | Dr. Jennifer Roeland, OB/GYN, Women's Hormonal Health Coach Jennifer's Journey toward Holistic Health As a former sufferer of PCOS and hypothyroidism, Jen has been on the hormone roller coaster. From digestion issues to fatigue, to hair loss, to brain fog and infertility. Even as a doctor, she was blown off by doctors who said my labs were normal. But she knew something was wrong, it had been 18 months and no baby. Jen spent countless hours diving into nutrition and mind-body medicine. She learned how the gut is connected to hormone health. And medications like the birth control pill can wreak havoc on our bodies by depleting our bodies of nutrients and masking our symptoms but not actually treating the condition. She found out the CAUSE of her symptoms and used that information to focus on gut health, stress reduction, and the right exercise for my body. She was able to lose weight, clear skin, wake up rested, have more energy, and ultimately get pregnant. Holistic healing and postpartum Nutrients and food are keys in postpartum recovery. The benefits extend beyond the health of the mother, but to the child. Supporting the mother in breastfeeding, anxiety and depression, hormonal health, and gut health. All these things are intricately linked in our recovery and the development of your baby, as well as nurturing healthy relationships with those supporting you. Gut health & the importance of food Jen explains how there is very little nutritional training for doctors. So much is linked to our diet and gut health. The gut is coined as the second brain, and after pregnancy, can become unbalanced due to all the hormonal changes our bodies have endured. There isn't just one way to eat or support our gut. Depending on what ailments you are experiencing, adopting a holistic healing approach calls for personalized care. Whether you are looking to support a healthy cycle, skin, or digestion, there are different approaches you can take without needing to resort to a doctor's prescription. What holistic healing looks like Holistic healing is not a pill. It is a process of trial and error. There are no quick fixes when it comes to your health. But adopting these changes into your every day life will have long term effects. You will know what you need to support your health and your child's health. You can't control the changes pregnancy can do to your body, but you can control what you put into your body. Balancing your plate will give you a better understanding of what your body needs and how you can support it in a natural way. Topics covered How healing is food? (2:06) Integrating nutrition into your work as an OB/GYN (6:32) The timeline of holistic healing (9:48) Supporting a healthy cycle postpartum (13:43) Advocating for more postpartum support in the medical community (19:56) Advice if you feel you are not being heard by your doctor (24:17) Nutrition & food is key to postpartum (30:51) Final question (39:48) Resources Dr. Roeland's coaching and courses Additional resources Check out the Hello Postpartum eBook shop for expert-written postpartum recovery guides

De zorgen om de enorme prijsstijgingen nemen toe, maar in Den Haag blijft het vooralsnog oorverdovend stil. Is het niet de hoogste tijd om in te grijpen? Ons Breekijzer: Den Haag moet terugkomen van reces om de enorme prijsstijgingen aan te pakken. Nederland is inmiddels het land met de hoogste gasprijs van alle EU-landen. Energiecontracten worden alleen maar duurder. Ook in de supermarkt lopen de prijzen verder op. Gemiddeld betalen we bijna twintig procent meer. Volgens het Nibud zitten ruim een miljoen mensen in de problemen. Zorgwekkend, maar wat gebeurt er in Den Haag? In het panel: Victor Pak, journalist bij EW Tom de Nooijer, partijleider van CVO in Oldebroek De breekijzer-experts: Roeland van Geuns, Lector Armoede Interventies aan de Hogeschool van Amsterdam Dirk-Jan Wolfert, directeur van de Vastelastenbond See omnystudio.com/listener for privacy information.

Meet The Natural Freedom League. You know Will Keller by now if you watch the show regularly. Meet his P.I.C. John Roeland! Together they make The Natural Freedom League! They dedicate their time and energy to performing The Great Work by lending their voices to speaking Truth to Power. Waking people up with the power of voice and technology is not the only thing they do; they are also known for their 'man on the street' approach as well. These two get involved in their communities by setting up a station in public locations to spread the word about Natural Law. To find more from The Natural Freedom League please visit their website at the link below: https://naturalfreedomleague.com/ The F.U.N.L. 2 conference is coming up! September 10 & 11 of 2022! To learn more about this excellent event and the wonderful speakers that you will hear from, please visit the link below to register so you don't miss out on all the fun! https://freedomundernaturallaw.com/ Of course, as always, I want to encourage all of you to go to The One Great Work Network to find a speaker that you can relate with. Please visit the link below to begin. https://onegreatworknetwork.com/ To learn more about the first Shattering the Illusion online event, please visit the link below to meet the speakers and find out everything you need to know to watch on September 24, 2022. https://www.shatteringtheillusion.info/ Visit James' website to find more from him including the archived podcasts of the past! http://www.freeyourmindne.com/ See you each Saturday night at 9 pm EST/ 6 pm PST! --- Support this podcast: https://anchor.fm/hitchhikersguidetotruth/support

De voedselcrisis, inflatie én aandeelhouders zetten Unilever flink onder druk. Het bedrijf reageert door zich te reorganiseren en 1500 banen te schrappen. Gaat dat de groei weer aanjagen? Hanneke Faber, president van Global Foods & Refreshment bij Unilever, is te gast in BNR Zakendoen Macro-econoom Elke dag, even over twaalf, bespreekt presentator Thomas van Zijl met een macro-econoom de economische stand van zaken. Vandaag met Marijn Jongsma, redacteur macro-economie bij het Financieele Dagblad. Economenpanel Wat zijn de gevolgen van de renteverhoging van de ECB? En: Krijgt Kaag met haar taskforce de overheidsboekhouding op orde? Dat en meer bespreken we om 13.00 in het economenpanel met: -Wimar Bolhuis (docent aan de Universiteit Leiden en nu hoofdeconoom bij Ecorys) -Hans Stegeman (Head of research and Investment Strategy bij Triodos) Luister l Economenpanel Inzichtgesprek Huboo, een Britse logistieke dienstverlener voor online retailers, weet in te spelen op de post-Brexit grensproblemen. Via Huboo wordt de handel tussen het Verenigd Koninkrijk en de EU namelijk weer wat soepeler. Te gast is Roeland van Duifhuizen, Regional Sales Manager van Huboo. Zakenpartner Haar roots liggen in de tv-wereld en ze heeft onder andere gewerkt bij Warner Bros als formatdeveloper, maar toen maakte ze een kantelpunt. Ze vond haar plaats aan de wieg van de influencer-wereld en ze richtte het succesvolle brandingbedrijf &.agency op samen met een compagnon. De zakenpartner van deze week is Sophie van der Schaft, mede-eigenaar van &.agency en &.talent. Contact & Abonneren BNR Zakendoen zendt elke werkdag live uit van 12:00 tot 14:30 uur. Je kunt de redactie bereiken via e-mail en Twitter. Abonneren op de podcast van BNR Zakendoen kan via bnr.nl/zakendoen, of via Apple Podcast en Spotify. See omnystudio.com/listener for privacy information.

As we look to build intentional communities with others outside of modern society, by which rules should we live? John Roeland from Natural Freedom League joins Ben for a discussion on Natural Law. The second half of the discussion available only on Rokfin: https://rokfin.com/OdinsAlchemy John can be found at: https://naturalfreedomleague.com/

datum: 5 en 6 januari gasten: Xander De Rycke, Amelie Albrecht en Jens Mekanik Lambrigts Een andere grote spin: Spider-Man. We bespreken de nieuwe film: No Way Home (met spoilers)en de oude films. Jens geeft wat toelichting rond de comics en Amelie had nog nooit een Marvel gerelateerde film gezien en bekeek niet Spider-Man (2002) maar Spider-Man: Homecoming. Met dank aan de fotoshoppende luisteraars: Brecht, Kevin en Roeland.  

In our 8th episode, our co-founder Ori (@oritheorca) welcomes Aflatoun's CEO, Roeland Monasch (@Aflatoun)! Give it a listen and learn about Aflatoun's previous work as a nonprofit focused on global education and to hear more on their plans to use the Orcanaut's mint revenue donation to build DeFi education for kids!

S02E05 - Brett Roeland by Burnie & PC

Grote drukte in de Herestraat op de laatste dag dat de niet-essentiële winkels open zijn. Winkelpubliek, Forum Groningen, Groninger Museum en Silvia reageren op de lockdown. Sylvia Görtz heeft een nagelsalon in Haren en moet weer dicht en wethouder Roeland van der Schaaf over nieuwe plannen voor de Grote Markt. 

Roeland is the organizer of HiveFest (formerly known as SteemFest). His childhood represents the quintessential Dutch upbringing. Born in a small peninsula in the Southwest of the Netherlands, Roeland lived the first year of his life in a windmill, which was next door to a pancake shop, owned by his father. Fast-forward to 1996, while in hotel school, Roeland made monthly payments on a laptop because he needed to access excel sheets for his assignments. But while others in Roeland's program were working part-time jobs in their spare time, Roeland went beyond spreadsheets and taught himself how to build websites and mobile apps. His passion for technology naturally led him to discover the world of crypto in the early days. Since then, Roeland has become best known for his role as organizer of every SteemFest since 2016, which has transitioned into a HiveFest, which takes place virtually this year on Dec. 18 and 19, 2020.